Ascentage Pharma Group International American Depository Shares (AAPG)

Nasdaq: AAPG · Pharmaceutical Preparations · Suzhou , Jiangsu, CN · filing with the SEC since 2024

Full chart Alerts Compare

Grade6.2

◀ Past 7.5● Present 5.6▶ Future 6.0

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Ascentage Pharma Group International American Depository Shares

Nine metrics read from its own filings, by tense

Headline grade

6.2/10

◀ Past7.525% of the headline

● Present5.635% of the headline

▶ Future6.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.5/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2024.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Ascentage Pharma Group International American Depository Shares' filings since 2024 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.5/10

What has it actually done, year after year?

+116.1% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 75th percentile among 323 sector filers · read for its customers

From the record

Ascentage Pharma Group International American Depository Shares' 3 filed years say what it did: revenue went from CNY 210 million in fiscal 2022 to CNY 981 million in fiscal 2024, up 116.1% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span116.1%top 7% of its family
the share of years revenue rosetop 8% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

7.0/10

How has it treated the people who own it?

SI estimate 7.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 70th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 30% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ascentage Pharma Group International American Depository Shares's shareholder treatment is put at 7.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 30% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.6/1035% of the headline grade · 1 of 3 filed, 2 estimated

Financial health

SI estimate

5.1/10

Is it financially healthy right now?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 480 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: No balance sheet on file, so the desk assumes the typical reading of its industry family, the median of 480 members with one.
What the record cannot read: No balance sheet on file.
How it was reasoned: family median, 480 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ascentage Pharma Group International American Depository Shares's financial health is put at 5.1 of 10 with a confidence of 20 of 100, because no balance sheet on file, so the desk assumes the typical reading of its industry family, the median of 480 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Industry position

as filed

7.5/10

How strong is its position in its industry?

top 25% of 315 in its family; net margin -41.4%.

weight 22% of this tense · 75th percentile among 315 sector filers · read for its customers

From the record

Ascentage Pharma Group International American Depository Shares' standing among 315 graded names in its industry family: revenue of CNY 981 million in fiscal 2024 is not ranked by size, since the family reports in another currency; a net margin of -41.4% ranks in the top 39%; revenue growth of 116.1% a year over the last 2 filed years ranks in the top 11% (its annual reports).

What it rests on

net margin-41.4%top 39% of its family
three-year revenue growth116.1%top 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-19 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-19 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ascentage Pharma Group International American Depository Shares's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-19 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.0/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

6.9/10

How much room does it have to grow?

top 31% of 273 in its family for room to expand.

weight 33% of this tense · 69th percentile among 273 sector filers · read for itself

From the record

Ascentage Pharma Group International American Depository Shares' room to grow, from the newest filed statements (fiscal 2024): cash from operations less capital spending is -13.8% of revenue (top 34%); a gross margin of 97% (top 7%); research spending of 96.6% of revenue (bottom 48%) (its annual report).

What it rests on

cash from operations less capital spending against revenue-13.8%top 34% of its family
gross margin97.0%top 7% of its family
research spending against revenue96.6%bottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

5.7/10

What could actually drive growth from here?

top 43% of 306 in its family for growth drivers.

weight 45% of this tense · 57th percentile among 306 sector filers · read for its customers

From the record

Ascentage Pharma Group International American Depository Shares' growth drivers, from the filed years to fiscal 2024: revenue grew 116.1% a year over the last three filed years against 116.1% over all 3, speeding up (top 40% of its family); the newest year grew 340.4% (top 9%); research spending grew 12.9% a year (top 34%); capital spending grew -65.4% a year (bottom 10%) (its annual reports). Ascentage Pharma Group International American Depository Shares tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
the newest year's revenue growth340.4%top 9% of its family
three-year growth of research spending12.9%top 34% of its family
three-year growth of capital spending-65.4%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ascentage Pharma Group International American Depository Shares's expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton AAPG · research, not advice